Identification of Novel Colistin Resistance Genes in an Extremely Colistin Resistant Pseudomonas aeruginosa Clinical Isolate

M Northwestern Medicine[®]

Feinberg School of Medicine

Abstract

Background

Pseudomonas aeruginosa (PA) readily acquires genomic mutations and exogenous genetic elements that confer antimicrobial resistance (AMR). With the rise in AMR, there are limited antibiotics available to treat multidrug-resistant (MDR) PA. As such, clinicians have returned to previously used antibiotics. Colistin, sidelined for neurotoxicity and nephrotoxicity, has returned to clinical practice as a viable but suboptimal option for MDR-PA treatment. The most common mechanism of resistance to colistin involves modifications of the lipid A moiety within the bacterial lipopolysaccharide (LPS) [1, 2]. Following the identification of a MDR PA isolate, BWH047, we experimentally determined its colistin MIC to be > 1,280 µg/mL and used genomic approaches to identify novel genetic mechanisms of extreme colistin resistance [3].

Methods

We created a random, saturated transposon (Tn) insertion library in PA BWH047 using the *Himar1* mariner system. After exposure of the library to 640 µg/mL colistin for 10 hours, genomic DNA was harvested, and the Tn insertion sites were sequenced. Insertion sequencing (INSeq) analysis was performed. We identified 27 genes conditionally important for BWH047 growth in the presence of colistin. We initially selected five targets *arnC*, *dedA*, *wapH*, *speE2*, and *bchE* and tested their impact on colistin resistance using standard broth microdilution methods.

Results

Of our deletion mutants, three showed loss of resistance to colistin. ArnC was chosen as a positive control as its role in colistin resistance in PA is well described [1]. Colistin MICs of BWH047 $\Delta arnC$, $\Delta dedA$, $\Delta wapH$, $\Delta speE2$, and $\Delta bchE$ were determined to be 0.5, 0.5, 1, > 1,280 and > 1280 µg/mL, respectively.

Conclusions

Here, we used INSeq to identify novel genes involved in extreme colistin resistance. Thus far, we have identified two new candidate genes *dedA* and *wapH*, critical for colistin resistance in PA BWH047. Neither gene has been associated with colistin resistance in PA. However, *dedA* orthologs in Burkholderia thailandenesis and Klebsiella pneumoniae have been shown to be important for colistin resistance [4,5]. The gene *wapH* is part of the LPS core oligosaccharide biosynthetic pathway and its discovery hints that additional alterations in the bacterial outer membrane may impact colistin resistance

Background and Library Generation

Clinical and Isolate Background

- BWH047 was isolated from a BAL from a patient on protracted inhaled colistin therapy
- Kirby-Bauer and broth microdilution (BMD) testing revealed that BWH047 was a multidrug-resistant PA isolate
- To determine the actual minimal inhibitory concentration (MIC) for colistin, 10x BMD MICs were performed. The MIC of BWH047 was determined to be >1280 µg/mL [3]
- Genomic sequencing did not reveal the presence of any canonical colistin resistance mutations or the presence of *mcr* genes which confer colistin resistance. [3]

Mechanisms of Colistin Resistance

- Colistin, a cationic polypeptide disrupts negatively charged bacterial membranes leading to membrane instability and cell death.
- Common mechanisms of resistance include modification to LPS, specifically lipid A, with phosphoethanolamine (pEtN) and 4-amino-4-deoxy-L-arabinose (L-Ara4N) [1,2]
- Additional resistance mechanisms include:
 - Upregulation of efflux pumps • Upregulation of two-component
 - systems Increased biofilm formation



Samuel W.M. Gatesy¹, Hanna K. Bertucci¹, Madeleine B. Vessely^{1,2}, Aliki Valdes², Arghavan Alisoltanidehkordi¹⁻³, Egon A. Ozer^{1,2}, Francisco Marty, John J. Mekalanos⁴, Alan R. Hauser¹⁻³, and Kelly E. R. Bachta^{1,3*} ¹Division of Infectious Diseases, Northwestern University, Feinberg School of Medicine, Chicago, IL; ³Center for Pathogen Genomics and Microbiology-Immunology, Northwestern University, Feinberg School of Medicine, Chicago, IL; ³Center for Pathogen Genomics and Microbiology-Immunology, Northwestern University, Feinberg School of Medicine, Chicago, IL; ³Center for Pathogen Genomics and Microbiology-Immunology, Northwestern University, Feinberg School of Medicine, Chicago, IL; ³Center for Pathogen Genomics and Microbiology-Immunology, Northwestern University, Feinberg School of Medicine, Chicago, IL; ³Center for Pathogen Genomics and Microbiology-Immunology, Northwestern University, Feinberg School of Medicine, Chicago, IL; ³Center for Pathogen Genomics and Microbiology-Immunology, Northwestern University, Feinberg School of Medicine, Chicago, IL; ³Center for Pathogen Genomics and Microbiology-Immunology, Northwestern University, Feinberg School of Medicine, Chicago, IL; ³Center for Pathogen Genomics and Microbiology-Immunology, Northwestern University, Feinberg School of Medicine, Chicago, IL; ³Center for Pathogen Genomics and Microbiology-Immunology, Northwestern University, Feinberg School of Medicine, Chicago, IL; ³Center for Pathogen Genomics and Microbiology-Immunology, Northwestern University, Feinberg School of Medicine, Chicago, IL; ³Center for Pathogen Genomics and Microbiology-Immunology, Northwestern University, Feinberg School of Medicine, Chicago, IL; ³Center for Pathogen Genomics and Microbiology-Immunology, Northwestern University, Feinberg School of Medicine, Chicago, IL; ³Center for Pathogen Genomics and Microbiology-Immunology, Northwestern University, Feinberg School of Medicine, Chicago, IL; ³Center for Pathogen Genomics and Microbiology-Immunology, Northwestern University, Feinberg School of Medicine, Chicago, IL; ³Center for Pathogen Genomics and Microbiology-Immunology, Northwestern University, Feinberg School of Medicine, Chicago, IL; ³Center for Pathogen Havey Institute for Global Health, Northwestern University, Chicago, IL; ⁴ Department of Microbiology, Harvard Medical School, Boston, MA.

134251-CSDG-20-053-01-MPC (Awarded to K. Bachta).



*kelly.bachta@northwestern.edu